Cover Image

Editorial: Pharmacological and biochemical perspectives of kinase inhibitors in cancer and COVID-19 therapeutics

Saved in:

Bibliographic Details
Main Authors:	Balakumar Chandrasekaran (Author), Muthupandian Saravanan (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume I
by: Balakumar Chandrasekaran, et al.
Published: (2022)

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review
by: Nem Kumar Jain, et al.
Published: (2023)

Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
by: Rajashri R. Naik, et al.
Published: (2022)

Janus Associated Kinases Inhibitors in the Pharmacological Thera
by: Daniela Santos1, et al.
Published: (2017)

Therapeutic Potential of Mitotic Kinases' Inhibitors in Cancers of the Gastrointestinal System
by: Aadil Javed, et al.
Published: (2022)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024)

Editorial: Anti-cancer bioactive molecules from microbial sources
by: Bishwambhar Mishra, et al.
Published: (2023)

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment
by: Oana-Maria Thoma, et al.
Published: (2021)

Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer
by: Faez Iqbal Khan, et al.
Published: (2020)

The Role of the Kinase Inhibitors in Thyroid Cancers
by: Francesca Cuomo, et al.
Published: (2022)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
by: Abbaspour Babaei M, et al.
Published: (2016)

Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
by: Md Sazzad Hassan, et al.
Published: (2021)

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics
by: Shraddha Parate, et al.
Published: (2021)

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
by: Yoshiya Tanaka
Published: (2023)

Kinase Inhibitor Screening Displayed <i>ALK</i> as a Possible Therapeutic Biomarker for Gastric Cancer
by: Felipe Pantoja Mesquita, et al.
Published: (2022)

Cancer Therapy Resistance: Choosing Kinase Inhibitors
by: Carmela Dell'Aversana, et al.
Published: (2024)

Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease
by: Huo R, et al.
Published: (2022)

The Kinase Specificity of Protein Kinase Inhibitor Peptide
by: Yao Chen, et al.
Published: (2021)

Cardiovascular safety of tyrosine kinase inhibitors: Putting their "QT-phobia" in perspective
by: Rashmi Shah
Published: (2016)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
by: Mitra Rezaei, MD, et al.
Published: (2022)

Kinase Inhibitor Library Screening Identifies the Cancer Therapeutic Sorafenib and Structurally Similar Compounds as Strong Inhibitors of the Fungal Pathogen <i>Histoplasma capsulatum</i>
by: Charlotte Berkes, et al.
Published: (2021)

Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis
by: Hiroshi Tsushima, et al.
Published: (2017)

Innovations in the systemic treatment of medullary thyroid cancer with kinase inhibitors
by: Wiktoria Lipczyńska, et al.
Published: (2023)

Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
by: Wennan Zhao, et al.
Published: (2017)

Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies
by: Made Putra Semadhi, et al.
Published: (2017)

Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives
by: Leor Roseman, et al.
Published: (2022)

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
by: Timothy J. Turner, et al.
Published: (2024)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
by: José Rivera-Torres, et al.
Published: (2019)

The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis
by: Indra Wijaya, et al.
Published: (2021)

Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
by: Milo Gatti, et al.
Published: (2021)

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later
by: Max Robles-Nasta, et al.
Published: (2024)

Current Biochemical Applications and Future Prospects of Chlorotoxin in Cancer Diagnostics and Therapeutics
by: Sbonelo Khanyile, et al.
Published: (2019)

Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023)

Pharmacokinetic Boosting of Kinase Inhibitors
by: Niels Westra, et al.
Published: (2023)

Editorial: Phytochemicals in cancer prevention and therapeutics: Current advancement and future perspective
by: Subrata Kumar Pore, et al.
Published: (2023)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
by: Andreia Gameiro, et al.
Published: (2021)

Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
by: Aisha Alsfouk
Published: (2021)

Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer
by: Sandeep Kumar, et al.
Published: (2020)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
by: Shangwei Zhong, et al.
Published: (2022)

Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy
by: Nikolaos Kokkorakis, et al.
Published: (2024)